Horsham, PA (PRWEB) May 6, 2006
SCIREX Corporation announced today the appointment of William P. Birmingham, PharmD as Director of Safety and Pharmacovigilance, Department of Medical Management and Safety. Reporting to Samer E. Kaba, M.D., Vice President Clinical Research & Medical Management, Dr. Birmingham will be responsible for the direction and management of all safety-related activities and issues for clinical trials managed by SCIREX and will coordinate the company’s worldwide activities in the development and execution of pharmacovigilance and risk minimization plans for the company’s research projects.
Dr. Birmingham brings to SCIREX a wealth of experience in safety monitoring and risk management planning for clinical trials. His prior appointments include service as Manager, Safety Evaluation and Risk Management at GlaxoSmithKline, as Director, Drug Safety and Pharmacovigilance at Vicuron Pharmaceuticals, and as Director, Global Adverse Event Reporting at Wyeth. His clinical experience includes work as a clinical pharmacist at Children’s Hospital of Philadelphia, and as a clinical pharmacist and general clinical resident at Philadelphia’s Thomas Jefferson University Hospital. Dr. Birmingham received his Doctor of Pharmacy degree from the College of Pharmacy at the University of Kentucky and has served as a clinical instructor at the Philadelphia College of Pharmacy and Science.
SCIREX Corporation (http://www.scirex.com) is an industry leader in the delivery of comprehensive Phase I-IV drug development services to the global pharmaceutical and biotechnology industry. SCIREX’s services include clinical trial management, drug development planning, protocol design, submission services, regulatory affairs consulting, investigator and patient recruitment, data management, statistical analysis, medical writing and offers an array of technology solutions. SCIREX brings experience from more than 1,000 clinical studies involving well over 135,000 patients in most major therapeutic areas, with specific expertise in pain and inflammation, and neurological and psychiatric disorders. SCIREX is a wholly-owned subsidiary of Omnicom Group, Inc. (NYSE: OMC) (http://www.omnicomgroup.com).
For more information contact Blythe Vito, SCIREX Corporate Marketing at (215) 907-1330 x1054, or visit http://www.scirex.com.
# # #